Risultati della ricerca - Daniel Selness

  • Mostra 1 - 2 risultati su 2
Raffina i risultati
  1. 1
    Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study <scp>MT</scp>‐1186‐<scp>A02</scp>)

    Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study <scp>MT</scp>‐... di Jeffrey D. Rothstein, Angela Genge, Amélia M. Silva, Lorne Zinman, Marvin Chum, Adriano Chiò, Gen Sobue, Masashi Aoki, Hiide Yoshino, Manabu Doyu, Daniel Selness, Vesna Todorović, Noah J. Sasson, Manabu Hirai, Fumihiro Takahashi, Alejandro Salah, Art Wamil, Stephen Apple

    Pubblicazione 2025
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment

    Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment di Angela Genge, Gary L. Pattee, Gen Sobue, Masashi Aoki, Hiide Yoshino, Philippe Couratier, Christian Lunetta, Susanne Petri, Daniel Selness, Vesna Todorović, Noah J. Sasson, Manabu Hirai, Fumihiro Takahashi, Alejandro Salah, Stephen Apple, Art Wamil, Alexander Kalin, Carlayne E. Jackson

    Pubblicazione 2025
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: